AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Saving lives, Reducing costs
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
What problems do we solve?According to WHO, 14 million cancer patients are treated annually with conventional chemotherapy.
ProblemNearly 50% of these chemotherapy patients do not get much benefit from the treatments.
They experience all the anguishes of chemotherapy but their tumors progress and their condition persists.
Physicians then have to switch to a different regimen of chemotherapy, if it is not too late!
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
AccuDava solution
We have developed an unprecedented molecular process to improve efficacy of personalizing cancer chemotherapy.
Our test enables physicians to avoid ineffective drugs and select suitable treatments, based on a patient’s tumor molecular characteristics – before treatment begins.
All this from a 60-minute test on a tumor sample.
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
AccuDava’s technology is based on the identification of two “Cell-Surface Glycan Biomarkers”
Specificity of AccuDava BiomarkersIt is on the cell-surface not within the cell.It is a carbohydrate motif, not genomic or protein.
- Glycans are dynamic molecules involved in cell-signaling, and on the front line of cell communication and defense.
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Chemo-sensitivecancer cell
(10X more biomarker on chemo-susceptible than
chemo-resistant)
Chemo-Resistantcancer cell
Nucleus
Glycan biomarker
Nucleus
Presentation of the cell-surface glycan biomarker over-expression on cancer cells
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Detecting Method of the glycan biomarker
tumor
tumor
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Histochemical staining of retrospective human ovarian cancer tumor sections
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Science teamNahid Razi, Ph.D., Founder and Principle Investigator
Afshin Bahador, M.D., Director of Clinical ResearchOBGYN and Surgical oncologist South Coast Gynecologic Oncology, Inc.
Nissi Varki, M.D., Professor of Pathology at UCSD,Director of the UCSD histology and pathology laboratory
Nathalie Scholler, M.D., Ph.D., Professor of OBGYN and Oncology at University of Pennsylvania,
Specialist in ovarian cancer biomarkers- MesoMarkTM
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Management TeamNahid Razi - President
Hedi Jafari, MBA - CFOFinancial manager at UCSD
Afshin Bahador, MD - Managing partner
David Larson - Business advisorCFO/COO True Diagnostics
Scientific AdvisorProfessor Ulf Lindahl- Senior member of the Swedish Royal Academy of Science, member of the Nobel Prize committee
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Achievements10 years of investigations identified two “glycan biomarkers” for drug responseDeveloped assays for detecting those biomarkersVerified the assays' reliability, reproducibility and specificity on human cancer specimensValidated the clinical correlation of the biomarkers with drug efficacy, on retrospective ovarian cancer tumor sectionsApplied for 2 patents, received 1, the other in process
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
Intellectual Property
Two Patents filed by Knobbe-MartensOne issued patent (2009)One pending (recently filed)Filed under the name of Nahid Razi, Ph.D.
AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics
2 milestones to MarketMilestone #1 - Preclinical Verification100-200 ovarian cancer patients (sites identified)12-18 monthsCreate protocols for Clinical trial
Milestone #2 - Clinical Studies + PMA (FDA Clearance)FDA required number of ovarian cancer patients18-24 months (est.)Produce data to support PMA for FDA approval